📊 BCDA Key Takeaways
Is BioCardia, Inc. (BCDA) a Good Investment?
BioCardia faces severe financial distress with negative shareholders' equity of -$1.1M, indicating technical insolvency. The company has zero revenue, negative operating cash flow of -$1.7M, and a critical liquidity crisis with current ratio of 0.41x, meaning current liabilities are 2.4x current assets with less than one year of cash runway at current burn rates.
BioCardia's fundamentals are very weak: revenue has effectively collapsed to zero while operating and net losses remain large relative to its asset and equity base. The company does have meaningful cash and no long-term debt, but current cash burn and deeply negative returns on assets and equity indicate a fragile financial position unless commercialization or funding improves materially.
BioCardia, Inc. Key Strengths (BCDA)
- Minimal capital expenditure requirements suggests asset-light business model
- Retains $951K in cash reserves providing short-term operational window
- Operating in biological products sector which may contain proprietary technology or pipeline value
- Cash balance of $5.29M provides near-term operating flexibility
- No meaningful long-term debt reduces financial leverage risk
- Current and quick ratios of 1.62x indicate acceptable short-term liquidity for now
BCDA Stock Risks: BioCardia, Inc. Investment Risks
- Negative stockholders' equity of -$1.1M indicates technical insolvency and balance sheet deterioration
- Current ratio of 0.41x signals acute liquidity crisis with inability to meet short-term obligations
- Zero revenue generation with -100% YoY decline indicates complete loss of commercial traction
- Operating cash burn of -$1.7M with limited runway suggests imminent need for capital infusion or restructuring
- Total liabilities exceed total assets by $1.1M creating existential solvency risk
- Revenue fell 87.8% year over year to effectively zero, raising major concerns about business viability and commercialization progress
- Operating cash flow of -$4.94M and net loss of -$6.24M imply continued heavy cash burn
- ROE of -237.7% and ROA of -101.6% show severe capital inefficiency and weak underlying economics
Key Metrics to Watch
- Monthly cash burn rate and time-to-depletion of cash reserves
- Any revenue generation or customer contracts
- Capital raising activities or equity financing announcements
- Liability reduction or debt restructuring efforts
- Strategic partnership, merger, or acquisition activity
- Quarterly revenue recovery and consistency of commercial or partnership income
- Cash runway based on operating cash burn versus ending cash balance
BioCardia, Inc. (BCDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BCDA Profit Margin, ROE & Profitability Analysis
BCDA vs Healthcare Sector: How BioCardia, Inc. Compares
How BioCardia, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioCardia, Inc. Stock Overvalued? BCDA Valuation Analysis 2026
Based on fundamental analysis, BioCardia, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioCardia, Inc. Balance Sheet: BCDA Debt, Cash & Liquidity
BCDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioCardia, Inc.'s revenue has declined by 94% over the 5-year period, indicating business contraction. The most recent EPS of $-2.90 indicates the company is currently unprofitable.
BCDA Revenue Growth, EPS Growth & YoY Performance
BCDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.5M | $-0.24 |
| Q2 2025 | N/A | -$1.6M | $-0.40 |
| Q1 2025 | N/A | -$2.3M | $-0.59 |
| Q3 2024 | N/A | -$1.6M | $-0.61 |
| Q2 2024 | $3.0K | -$1.6M | $-0.88 |
| Q1 2024 | $55.0K | -$2.3M | $-0.09 |
| Q3 2023 | $212.0K | -$2.5M | $-0.12 |
| Q2 2023 | $43.0K | -$2.5M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioCardia, Inc. Dividends, Buybacks & Capital Allocation
BCDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioCardia, Inc. (CIK: 0000925741)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCDA
What is the AI rating for BCDA?
BioCardia, Inc. (BCDA) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCDA's key strengths?
Claude: Minimal capital expenditure requirements suggests asset-light business model. Retains $951K in cash reserves providing short-term operational window. ChatGPT: Cash balance of $5.29M provides near-term operating flexibility. No meaningful long-term debt reduces financial leverage risk.
What are the risks of investing in BCDA?
Claude: Negative stockholders' equity of -$1.1M indicates technical insolvency and balance sheet deterioration. Current ratio of 0.41x signals acute liquidity crisis with inability to meet short-term obligations. ChatGPT: Revenue fell 87.8% year over year to effectively zero, raising major concerns about business viability and commercialization progress. Operating cash flow of -$4.94M and net loss of -$6.24M imply continued heavy cash burn.
What is BCDA's revenue and growth?
BioCardia, Inc. reported revenue of $0.0.
Does BCDA pay dividends?
BioCardia, Inc. does not currently pay dividends.
Where can I find BCDA SEC filings?
Official SEC filings for BioCardia, Inc. (CIK: 0000925741) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCDA's EPS?
BioCardia, Inc. has a diluted EPS of $-0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BCDA's fundamental grade?
Based on our AI fundamental analysis in June 2026, BioCardia, Inc. has a D grade with 93% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BCDA stock overvalued or undervalued?
Valuation metrics for BCDA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BCDA's AI grade for 2026?
Our dual AI analysis gives BioCardia, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCDA's free cash flow?
BioCardia, Inc.'s operating cash flow is $-1.7M, with capital expenditures of $3.0K.
How does BCDA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.41 (avg: 2).